Live, interactive, case based discussion with audience input - free CME/CE series
Session 1: Rapid Diagnosis, Risk Stratification, and Induction Therapies – Recording available soon
Session 2: Evolving Treatment in Cell Therapy and Transplant – November 19, 2025, 5:00 pm ET – 6:00 pm ET
Session 3: Coordinated Care from Treatment to Survivorship – Date/Time TBD
For each session you participate in, 1.0 credit/contact hour will be provided, for a total of 3.0possible credits. Participation at all three sessions is encouraged but not required to obtain CME/CE credits.
Description:
The Project ECHO model is designed to create a shared learning space for healthcare professionals through a series of educational sessions, fostering peer engagement and disseminating best practices in community care. Rapid advances in the treatment of acute leukemias, including acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), can make treatment decisions challenging. This virtual series will help providers stay up to date on the latest in disease-specific indications, treatment with HCT and cell therapy, and post-treatment monitoring and care coordination to improve patient outcomes.
Target Audience:
This activity is intended for hematology-oncology providers, including physicians, APPs and nurses who want to learn more about managing, treating, and monitoring patients with acute leukemias including those undergoing transplant and cell therapy.
Learning Objectives:
After completing this activity, the participant should be better able to:
Session 1:
• Describe disease-specific features and indications of acute leukemias, including subtype classification
• Identify tests used to diagnose acute leukemias
• Examine therapeutic options for induction
Session 2:
• Examine the appropriate treatments for acute leukemias and timing, including allogeneic HCT and CAR T-cell therapy
• Identify and manage treatment related side effects and treatment related complications
Session 3:
• Discuss post-treatment monitoring of long-term and late effects and surveillance strategies for detecting relapse post allogeneic HCT and CAR T-cell therapy
• Identify best practices in care coordination between hematology-oncology, transplant, and otherproviders involved in the care of patients
Faculty:
Alison Loren, MD, MSCE (chair/moderator, sessions 1, 2, 3)
Chief, Division of Hematology/Oncology
Director, Blood and Marrow
Transplantation
C. Willard Robinson Professor of Hematology/Oncology
University
of Pennsylvania
Philadelphia, PA
Shernan Holtan, MD (chair/moderator, sessions 1, 2, 3)
Chief, Blood and Marrow Transplantation Section
Department of
Medicine
Roswell Park Comprehensive Cancer Center
Buffalo, NY
Session 1
Alice S. Mims, MD, MSCR
Acute Leukemia Research Section
Head
Associate Division Director Clinical Research
Professor of
Medicine
The Ohio State University Comprehensive Cancer Center
Columbus,
OH
Courtney Bellomo, MD
Hematology
New York
Oncology Hematology
Albany, NY
Meghan McGrath, MSN, RN, AGACNP-BC
Clinical Trial Nurse
Navigator
Blood Cancer United
Washington, D.C.
Session 2
Clark Alsfeld, MD
Attending Physician
Ochsner MD
Anderson Cancer Center
Ochsner Health
New Orleans, LA
Alice S. Mims, MD, MSCR
Acute Leukemia Research Section
Head
Associate Division Director Clinical Research
Professor of
Medicine
The Ohio State University Comprehensive Cancer Center
Columbus,
OH
Darci Zblewski, APN, C-NP
Consultant
Blood Cancer
United
Washington, DC
Session 3
• Faculty TBD
Continuing Education Information
In support of improving patient care, this activity has been planned and
implemented by Blood Cancer United and Medical Learning Institute Inc. Medical
Learning Institute Inc is jointly accredited by the Accreditation Council for
Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy
Education (ACPE), and the American Nurses Credentialing Center (ANCC), to
provide continuing education for the healthcare team.
Physician Continuing Medical Education
Medical Learning
Institute Inc (MLI) designates this live activity for a maximum of
1.0 AMA PRA Category 1 Credits™.
Physicians should claim
only the credit commensurate with the extent of their participation in the
activity.
Registered Nursing Designation
Approval for nurses
has been obtained by the National Office of Blood Cancer United under Provider
Number CEP 5832 to award 1.0 continuing education contact hours through the
California Board of Registered Nursing.
Providers
This activity is provided by Blood Cancer
United, NMDP and Medical Learning Institute Inc, in collaboration with Project
ECHO.
There is no commercial support for this activity.
For questions, concerns, or assistance for people with disabilities or grievances, please contact us at: [email protected].